Identification
- Summary
Pentastarch is a plasma volume expander used as an adjunct in the management of shock due to hemorrhage, surgery, sepsis, burns or other trauma.
- Generic Name
- Pentastarch
- DrugBank Accession Number
- DB09111
- Background
Pentastarch is an artificial colloid (hydroxyethyl starch derivative). Pentastarch is characterized by presenting five hydroxyethyl groups, which signifies an approximate 50% hydroxyethylation. It is sold under the name Pentaspan by Bristol-Myers Squibb and is used for fluid resuscitation. When administered, pentastarch remains mainly in the circulatory system and hence, it is considered a plasma expander.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Synonyms
- Pentastarch
- External IDs
- ASL 607
Pharmacology
- Indication
The primary intended use of pentastarch is as a substitute for older colloids such as albumin or hetastarch for use in plasma volume expansion.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
Pentastarch is hydrolyzed by plasma amylase. This is more rapid and complete compared to hetastarch.
- Route of elimination
As a result of its lower molecular weight and lesser degree of substitution, pentastarch is eliminated from the circulation at a faster rate than hetastarch. Ordinarily, only 10% of an intravenous dose remains after 24 hours, and levels are undetectable after 4 to 7 days. Up to 70% of a dose is excreted in the urine within 24 hours.
- Half-life
~2.5 hours.
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Abacavir may decrease the excretion rate of Pentastarch which could result in a higher serum level. Aceclofenac Aceclofenac may decrease the excretion rate of Pentastarch which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Pentastarch which could result in a higher serum level. Acetaminophen Acetaminophen may decrease the excretion rate of Pentastarch which could result in a higher serum level. Acetazolamide Acetazolamide may increase the excretion rate of Pentastarch which could result in a lower serum level and potentially a reduction in efficacy. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- StarQuin (Biomed)
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- MOQ3RNM0SV
- CAS number
- 9005-27-0
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
References
- General References
- Younes RN, Yin KC, Amino CJ, Itinoshe M, Rocha e Silva M, Birolini D: Use of pentastarch solution in the treatment of patients with hemorrhagic hypovolemia: randomized phase II study in the emergency room. World J Surg. 1998 Jan;22(1):2-5. [Article]
- External Links
- PubChem Substance
- 347910411
- 816249
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Pentastarch
- FDA label
- Download (28.9 KB)
- MSDS
- Download (220 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count Not Available Completed Not Available Avascular Necrosis of Hip / Total Hip Replacement Arthroplasty 1 Not Available Completed Treatment Elective Cesarean Section 1 Not Available Unknown Status Treatment Cardiopulmonary Bypass / Surgery, Cardiac 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection Intravenous Solution Intravenous 10 g / 100 mL - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at September 17, 2015 21:45 / Updated at January 14, 2023 19:02